menu search
Trades24h logo
 Register
close Tap here to search
  1. Home

  2. News

  3. Stock Details

Subscribe To  

  Price Alert   Latest News   Economic Calendar News

XPHYF / XPhyto progressing its scientific approach to cannabis-based medicine and helping in the coronavirus fight

XPhyto progressing its scientific approach to cannabis-based medicine and helping in the coronavirus fight
German subsidiary, Vektor Pharma has developed an oral disintegrating film (ODF) for drug delivery Developed low-cost oral screening test to concurrently detect COVID-19 and non-COVID-19 coronaviruses Joint venture with Oettinger Brauerei for cannabis-infused beverages and products What Xphyto Therapeutics does: XPhyto Therapeutics Corp (CSE:XPHY) (OTCQB:XPHYF) (FRA:4XT) is a science-focused cannabis company developing analytical testing, processing, and formulation capability in Canada, while in Germany, it is focused on and research, cultivation, extraction, import, distribution, and manufacturing.  The firm listed on the Canadian Securities Exchange (CSE) on August 6, 2019, and on the Frankfurt exchange on August 13, 2019. Read More
Hmarkets Logo
Demo chevron_right Live Account chevron_right See Partner Details

Content Topics

Goldmoney

Inc

Xau

To

Xphyto

Progressing

Scientific

Approach

Cannabis based

Medicine

Helping

Coronavirus

Stock

XPHYF

Posted: Dec 15 2021, 23:39
Author Name: Proactive Investors
Views: 102255

XPHYF News  

XPhyto Therapeutics says pharmaceutical manufacturing expert Dr Florian A. Sahr has joined its European operations as project management head

By Proactive Investors
June 8, 2022

XPhyto Therapeutics says pharmaceutical manufacturing expert Dr Florian A. Sahr has joined its European operations as project management head

XPhyto Therapeutics Corp has announced that Dr Florian A. Sahr, a German-born and internationally-trained leader in drug formulation, technology trans more_horizontal

XPhyto Therapeutics advancing Rotigotine transdermal patch towards final pivotal study in fourth quarter this year

By Proactive Investors
April 4, 2022

XPhyto Therapeutics advancing Rotigotine transdermal patch towards final pivotal study in fourth quarter this year

XPhyto Therapeutics Corp has updated on the progress of its Rotigotine transdermal (TDS) patch product candidate, which is a non-ergoline dopamine ag more_horizontal

XPhyto Therapeutics makes strong progress on its psychedelic medicine programs and novel compounds

By Proactive Investors
February 22, 2022

XPhyto Therapeutics makes strong progress on its psychedelic medicine programs and novel compounds

XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) gave investors an update on the strong progress made by its wholly owned subsidiary XPhyto Laborator more_horizontal

XPhyto Therapeutics makes strong progress on its psychedelic medicine programs and novel compounds

By Proactive Investors
February 22, 2022

XPhyto Therapeutics makes strong progress on its psychedelic medicine programs and novel compounds

XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) gave investors an update on the strong progress made by its wholly owned subsidiary XPhyto Laborator more_horizontal

XPhyto Therapeutics makes strong progress on its psychedelic medicine programs and novel compounds

By Proactive Investors
February 22, 2022

XPhyto Therapeutics makes strong progress on its psychedelic medicine programs and novel compounds

XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) gave investors an update on the strong progress made by its wholly owned subsidiary XPhyto Laborator more_horizontal

XPhyto Therapeutics planning to release strategy on psychedelic medicine program in days as it updates on business divisions

By Proactive Investors
February 8, 2022

XPhyto Therapeutics planning to release strategy on psychedelic medicine program in days as it updates on business divisions

XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) told investors that it plans to update on its strategy for its psychedelic medicine program in comin more_horizontal

XPhyto Therapeutics planning to release strategy on psychedelic medicine program in days as it updates on business divisions

By Proactive Investors
February 8, 2022

XPhyto Therapeutics planning to release strategy on psychedelic medicine program in days as it updates on business divisions

XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) told investors that it plans to update on its strategy for its psychedelic medicine program in comin more_horizontal

XPhyto Therapeutics planning to release strategy on psychedelic medicine program in days as it updates on business divisions

By Proactive Investors
February 8, 2022

XPhyto Therapeutics planning to release strategy on psychedelic medicine program in days as it updates on business divisions

XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) told investors that it plans to update on its strategy for its psychedelic medicine program in comin more_horizontal

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

©2014-2024 All Rights Reserved. I.C

Hand-crafted & made with Love

logo close

Search within

Pages Search Results: